Skip to main content
Top
Published in: Digestive Diseases and Sciences 6/2020

01-06-2020 | Helicobacter Pylori | Review

What Would the Screen-and-Treat Strategy for Helicobacter pylori Mean in Terms of Antibiotic Consumption?

Authors: Mārcis Leja, Uga Dumpis

Published in: Digestive Diseases and Sciences | Issue 6/2020

Login to get access

Abstract

Several guidelines recommend the screen-and-treat strategy, i.e. active search for the presence of Helicobacter pylori infection and its eradication to prevent the possibility of gastric cancer. It is thought that a relatively short duration antibiotic regimen given once in a lifetime would not significantly increase overall antibiotic consumption. However, this would mean offering antibiotic treatment to the majority of the population in countries with the biggest burden of gastric cancer who would, therefore, have the greatest benefit from such a strategy. So far, no country has implemented an eradication strategy. With an example based on the current situation in Latvia, we have estimated the increase in antibiotic consumption if the screen-and-treat strategy was applied. Depending on the scenario that might be chosen, clarithromycin consumption would increase up to sixfold, and amoxicillin consumption would double if the recommendations of the current guideline in the local circumstances was applied. It appears that an increase in commonly used antibiotic consumption cannot be justified from the viewpoint of antibiotic stewardship policies. Solutions to this problem could be the use of antibiotics that are not required for treating life-threatening diseases or more narrow selection of the target group, e.g. young people before family planning to avoid transmission to offspring. Additional costs related to the increase in resistome should be considered for future cost-effectiveness modelling of the screen-and-treat strategy.
Literature
2.
go back to reference Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.CrossRefPubMed Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.CrossRefPubMed
4.
go back to reference Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health. 2016;4:e609–e616.PubMed Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health. 2016;4:e609–e616.PubMed
5.
go back to reference Plummer M, Franceschi S, Vignat J, Forman D, de Martel C. Global burden of gastric cancer attributable to Helicobacter pylori. Int J Cancer. 2015;136:487–490.PubMed Plummer M, Franceschi S, Vignat J, Forman D, de Martel C. Global burden of gastric cancer attributable to Helicobacter pylori. Int J Cancer. 2015;136:487–490.PubMed
6.
go back to reference Kuipers EJ. Review article: exploring the link between Helicobacter pylori and gastric cancer. Aliment Pharmacol Ther. 1999;13:3–11.PubMed Kuipers EJ. Review article: exploring the link between Helicobacter pylori and gastric cancer. Aliment Pharmacol Ther. 1999;13:3–11.PubMed
7.
go back to reference De Vries AC, Kuipers EJ. Review article: Helicobacter pylori eradication for the prevention of gastric cancer. Aliment Pharmacol Ther. 2007;26:25–35.PubMed De Vries AC, Kuipers EJ. Review article: Helicobacter pylori eradication for the prevention of gastric cancer. Aliment Pharmacol Ther. 2007;26:25–35.PubMed
8.
go back to reference Pimentel-Nunes P, Libanio D, Marcos-Pinto R, et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy. 2019;51:365–388.PubMed Pimentel-Nunes P, Libanio D, Marcos-Pinto R, et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy. 2019;51:365–388.PubMed
9.
go back to reference Stubljar D, Jukic T, Ihan A. How far are we from vaccination against Helicobacter pylori infection? Expert Rev Vaccines. 2018;17:935–945.PubMed Stubljar D, Jukic T, Ihan A. How far are we from vaccination against Helicobacter pylori infection? Expert Rev Vaccines. 2018;17:935–945.PubMed
10.
go back to reference Fallone CA, Moss SF, Malfertheiner P. Reconciliation of recent Helicobacter pylori treatment guidelines in a time of increasing resistance to antibiotics. Gastroenterology. 2019;157:44–53.PubMed Fallone CA, Moss SF, Malfertheiner P. Reconciliation of recent Helicobacter pylori treatment guidelines in a time of increasing resistance to antibiotics. Gastroenterology. 2019;157:44–53.PubMed
11.
go back to reference Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence consensus report. Gut. 2017;66:6–30.PubMed Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence consensus report. Gut. 2017;66:6–30.PubMed
12.
go back to reference Lonnberg S, Sekerija M, Malila N, et al. Cancer screening: policy recommendations on governance, organization and evaluation of cancer screening. In: European Guide on Quality Improvement in Comprehensive Cancer Control. Belgium: National Institute of Public Health, Slovenia, Scientific Institute of Public Health; 2017:39–76. http://www.cancercontrol.eu/guide-landing-page/. Accessed October 22, 2019. Lonnberg S, Sekerija M, Malila N, et al. Cancer screening: policy recommendations on governance, organization and evaluation of cancer screening. In: European Guide on Quality Improvement in Comprehensive Cancer Control. Belgium: National Institute of Public Health, Slovenia, Scientific Institute of Public Health; 2017:39–76. http://​www.​cancercontrol.​eu/​guide-landing-page/​. Accessed October 22, 2019.
13.
go back to reference Megraud F, Coenen S, Versporten A, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013;62:34–42.PubMed Megraud F, Coenen S, Versporten A, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013;62:34–42.PubMed
14.
go back to reference Brinkac L, Voorhies A, Gomez A, Nelson KE. The threat of antimicrobial resistance on the human microbiome. Microb Ecol. 2017;74:1001–1008.PubMedPubMedCentral Brinkac L, Voorhies A, Gomez A, Nelson KE. The threat of antimicrobial resistance on the human microbiome. Microb Ecol. 2017;74:1001–1008.PubMedPubMedCentral
15.
go back to reference Yap TW, Gan HM, Lee YP, et al. Helicobacter pylori eradication causes perturbation of the human gut microbiome in young adults. PloS One. 2016;11:e0151893.PubMedPubMedCentral Yap TW, Gan HM, Lee YP, et al. Helicobacter pylori eradication causes perturbation of the human gut microbiome in young adults. PloS One. 2016;11:e0151893.PubMedPubMedCentral
16.
go back to reference Malhotra-Kumar S, Lammens C, Coenen S, Van Herck K, Goossens H. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. Lancet. 2007;369:482–490.PubMed Malhotra-Kumar S, Lammens C, Coenen S, Van Herck K, Goossens H. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. Lancet. 2007;369:482–490.PubMed
17.
go back to reference Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64:1353–1367.PubMed Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64:1353–1367.PubMed
18.
go back to reference Coelho LGV, Marinho JR, Genta R, et al. IVth Brazilian consensus conference on Helicobacter pylori infection. Arq de Gastroenterol. 2018;55:97–121. Coelho LGV, Marinho JR, Genta R, et al. IVth Brazilian consensus conference on Helicobacter pylori infection. Arq de Gastroenterol. 2018;55:97–121.
19.
go back to reference Mahachai V, Vilaichone RK, Pittayanon R, et al. Helicobacter pylori management in ASEAN: the Bangkok consensus report. J Gastroenterol Hepatol. 2018;33:37–56.PubMed Mahachai V, Vilaichone RK, Pittayanon R, et al. Helicobacter pylori management in ASEAN: the Bangkok consensus report. J Gastroenterol Hepatol. 2018;33:37–56.PubMed
20.
go back to reference Fock KM, Katelaris P, Sugano K, et al. Second Asia-Pacific consensus guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol. 2009;24:1587–1600.PubMed Fock KM, Katelaris P, Sugano K, et al. Second Asia-Pacific consensus guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol. 2009;24:1587–1600.PubMed
21.
go back to reference Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017;112:212–239.PubMed Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017;112:212–239.PubMed
22.
go back to reference Herrero R, Parsonnet J, Greenberg ER. Prevention of gastric cancer. JAMA. 2014;312:1197–1198.PubMed Herrero R, Parsonnet J, Greenberg ER. Prevention of gastric cancer. JAMA. 2014;312:1197–1198.PubMed
23.
go back to reference Hiroi S, Sugano K, Tanaka S, Kawakami K. Impact of health insurance coverage for Helicobacter pylori gastritis on the trends in eradication therapy in Japan: retrospective observational study and simulation study based on real-world data. BMJ Open. 2017;7:e015855.PubMedPubMedCentral Hiroi S, Sugano K, Tanaka S, Kawakami K. Impact of health insurance coverage for Helicobacter pylori gastritis on the trends in eradication therapy in Japan: retrospective observational study and simulation study based on real-world data. BMJ Open. 2017;7:e015855.PubMedPubMedCentral
24.
go back to reference Choi KS, Jun JK, Suh M, et al. Effect of endoscopy screening on stage at gastric cancer diagnosis: results of the national cancer screening programme in Korea. Br J Cancer. 2015;112:608–612.PubMed Choi KS, Jun JK, Suh M, et al. Effect of endoscopy screening on stage at gastric cancer diagnosis: results of the national cancer screening programme in Korea. Br J Cancer. 2015;112:608–612.PubMed
25.
go back to reference Kim SG, Jung HK, Lee HL, et al. Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition. J Gastroenterol Hepatol. 2014;29:1371–1386.PubMed Kim SG, Jung HK, Lee HL, et al. Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition. J Gastroenterol Hepatol. 2014;29:1371–1386.PubMed
26.
go back to reference Tepeš B, Štabuc B. Slovenian society for gastroenterology and hepatology guidelines on the management of Helicobacter pylori infection. Zdrav Vestn. 2011;80:647–656. Tepeš B, Štabuc B. Slovenian society for gastroenterology and hepatology guidelines on the management of Helicobacter pylori infection. Zdrav Vestn. 2011;80:647–656.
27.
go back to reference Fallone CA, Chiba N, van Zanten SV, et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016;151:e14. Fallone CA, Chiba N, van Zanten SV, et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016;151:e14.
28.
go back to reference Malfertheiner P, Megraud F, O’Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III consensus report. Gut. 2007;56:772–781.PubMed Malfertheiner P, Megraud F, O’Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III consensus report. Gut. 2007;56:772–781.PubMed
29.
go back to reference Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht IV/Florence consensus report. Gut. 2012;61:646–664.PubMed Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht IV/Florence consensus report. Gut. 2012;61:646–664.PubMed
30.
go back to reference Wilson JM, Jungner YG. Principles and practice of mass screening for disease. Bol Oficina Sanit Panam. 1968;65:281–393.PubMed Wilson JM, Jungner YG. Principles and practice of mass screening for disease. Bol Oficina Sanit Panam. 1968;65:281–393.PubMed
31.
go back to reference Andermann A, Blancquaert I, Beauchamp S, Dery V. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ. 2008;86:317–319.PubMedPubMedCentral Andermann A, Blancquaert I, Beauchamp S, Dery V. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ. 2008;86:317–319.PubMedPubMedCentral
32.
go back to reference Zamani M, Ebrahimtabar F, Zamani V, et al. Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther. 2018;47:868–876.PubMed Zamani M, Ebrahimtabar F, Zamani V, et al. Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther. 2018;47:868–876.PubMed
33.
go back to reference Weck MN, Brenner H. Prevalence of chronic atrophic gastritis in different parts of the world. Cancer Epidemiol Biomark Prev. 2006;15:1083–1094. Weck MN, Brenner H. Prevalence of chronic atrophic gastritis in different parts of the world. Cancer Epidemiol Biomark Prev. 2006;15:1083–1094.
34.
go back to reference Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol. 2004;99:1833–1855.PubMed Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol. 2004;99:1833–1855.PubMed
36.
go back to reference Owens RC Jr, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis. 2008;46:S19–S31.PubMed Owens RC Jr, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis. 2008;46:S19–S31.PubMed
37.
go back to reference Trifan A, Girleanu I, Cojocariu C, et al. Pseudomembranous colitis associated with a triple therapy for Helicobacter pylori eradication. World J Gastroenterol. 2013;19:7476–7479.PubMedPubMedCentral Trifan A, Girleanu I, Cojocariu C, et al. Pseudomembranous colitis associated with a triple therapy for Helicobacter pylori eradication. World J Gastroenterol. 2013;19:7476–7479.PubMedPubMedCentral
38.
go back to reference Palleja A, Mikkelsen KH, Forslund SK, et al. Recovery of gut microbiota of healthy adults following antibiotic exposure. Nat Microbiol. 2018;3:1255–1265.PubMed Palleja A, Mikkelsen KH, Forslund SK, et al. Recovery of gut microbiota of healthy adults following antibiotic exposure. Nat Microbiol. 2018;3:1255–1265.PubMed
39.
go back to reference MacPherson CW, Mathieu O, Tremblay J, et al. Gut bacterial microbiota and its resistome rapidly recover to basal state levels after short-term amoxicillin-clavulanic acid treatment in healthy adults. Sci Rep. 2018;8:11192.PubMedPubMedCentral MacPherson CW, Mathieu O, Tremblay J, et al. Gut bacterial microbiota and its resistome rapidly recover to basal state levels after short-term amoxicillin-clavulanic acid treatment in healthy adults. Sci Rep. 2018;8:11192.PubMedPubMedCentral
40.
go back to reference Wright GD. The antibiotic resistome: the nexus of chemical and genetic diversity nature reviews. Microbiology. 2007;5:175–186.PubMed Wright GD. The antibiotic resistome: the nexus of chemical and genetic diversity nature reviews. Microbiology. 2007;5:175–186.PubMed
42.
go back to reference Forslund K, Sunagawa S, Kultima JR, et al. Country-specific antibiotic use practices impact the human gut resistome. Genome Res. 2013;23:1163–1169.PubMedPubMedCentral Forslund K, Sunagawa S, Kultima JR, et al. Country-specific antibiotic use practices impact the human gut resistome. Genome Res. 2013;23:1163–1169.PubMedPubMedCentral
43.
go back to reference Jonsson M, Qvarnstrom Y, Engstrand L, Swedberg G. Clarithromycin treatment selects for persistent macrolide-resistant bacteria in throat commensal flora. Int J Antimicrob Agents. 2005;25:68–74.PubMed Jonsson M, Qvarnstrom Y, Engstrand L, Swedberg G. Clarithromycin treatment selects for persistent macrolide-resistant bacteria in throat commensal flora. Int J Antimicrob Agents. 2005;25:68–74.PubMed
44.
go back to reference Jakobsson H, Wreiber K, Fall K, Fjelstad B, Nyren O, Engstrand L. Macrolide resistance in the normal microbiota after Helicobacter pylori treatment. Scand J Infect Dis. 2007;39:757–763.PubMed Jakobsson H, Wreiber K, Fall K, Fjelstad B, Nyren O, Engstrand L. Macrolide resistance in the normal microbiota after Helicobacter pylori treatment. Scand J Infect Dis. 2007;39:757–763.PubMed
45.
go back to reference Sjolund M, Wreiber K, Andersson DI, Blaser MJ, Engstrand L. Long-term persistence of resistant Enterococcus species after antibiotics to eradicate Helicobacter pylori. Ann Intern Med. 2003;139:483–487.PubMed Sjolund M, Wreiber K, Andersson DI, Blaser MJ, Engstrand L. Long-term persistence of resistant Enterococcus species after antibiotics to eradicate Helicobacter pylori. Ann Intern Med. 2003;139:483–487.PubMed
46.
go back to reference Jakobsson HE, Jernberg C, Andersson AF, Sjolund-Karlsson M, Jansson JK, Engstrand L. Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. PloS One. 2010;5:e9836.PubMedPubMedCentral Jakobsson HE, Jernberg C, Andersson AF, Sjolund-Karlsson M, Jansson JK, Engstrand L. Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. PloS One. 2010;5:e9836.PubMedPubMedCentral
47.
go back to reference Liou JM, Chen CC, Chang CM, et al. Long term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication a multicentre randomised trial. Lancet Infect Dis. 2019;19:1109–1120.PubMed Liou JM, Chen CC, Chang CM, et al. Long term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication a multicentre randomised trial. Lancet Infect Dis. 2019;19:1109–1120.PubMed
48.
go back to reference Bergman M, Huikko S, Huovinen P, Paakkari P, Seppala H, Finnish Study Group for Antimicrobial R. Macrolide and azithromycin use are linked to increased macrolide resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother. 2006;50:3646–3650.PubMedPubMedCentral Bergman M, Huikko S, Huovinen P, Paakkari P, Seppala H, Finnish Study Group for Antimicrobial R. Macrolide and azithromycin use are linked to increased macrolide resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother. 2006;50:3646–3650.PubMedPubMedCentral
49.
go back to reference Monnet DL, MacKenzie FM, Lopez-Lozano JM, et al. Antimicrobial drug use and methicillin-resistant Staphylococcus aureus, Aberdeen, 1996–2000. Emerg Infect Dis. 2004;10:1432–1441.PubMedPubMedCentral Monnet DL, MacKenzie FM, Lopez-Lozano JM, et al. Antimicrobial drug use and methicillin-resistant Staphylococcus aureus, Aberdeen, 1996–2000. Emerg Infect Dis. 2004;10:1432–1441.PubMedPubMedCentral
50.
go back to reference Linder JA. Editorial commentary: antibiotics for treatment of acute respiratory tract infections: decreasing benefit, increasing risk, and the irrelevance of antimicrobial resistance. Clin Infect Dis. 2008;47:744–746.PubMed Linder JA. Editorial commentary: antibiotics for treatment of acute respiratory tract infections: decreasing benefit, increasing risk, and the irrelevance of antimicrobial resistance. Clin Infect Dis. 2008;47:744–746.PubMed
51.
go back to reference Tamma PD, Cosgrove SE. Antimicrobial stewardship. Infect Dis Clin N Am. 2011;25:245–260. Tamma PD, Cosgrove SE. Antimicrobial stewardship. Infect Dis Clin N Am. 2011;25:245–260.
52.
go back to reference Guardabassi L, Prescott JF. Antimicrobial stewardship in small animal veterinary practice: from theory to practice. Vet Clin N Am Small Anim Pract. 2015;45:361–376. Guardabassi L, Prescott JF. Antimicrobial stewardship in small animal veterinary practice: from theory to practice. Vet Clin N Am Small Anim Pract. 2015;45:361–376.
55.
go back to reference Dyar OJ, Huttner B, Schouten J, Pulcini C, ESGAP. What is antimicrobial stewardship? Clin Microbiol Infect. 2017;23:793–798.PubMed Dyar OJ, Huttner B, Schouten J, Pulcini C, ESGAP. What is antimicrobial stewardship? Clin Microbiol Infect. 2017;23:793–798.PubMed
57.
go back to reference Molstad S, Lofmark S, Carlin K, et al. Lessons learnt during 20 years of the Swedish strategic programme against antibiotic resistance. Bull World Health Organ. 2017;95:764–773.PubMedPubMedCentral Molstad S, Lofmark S, Carlin K, et al. Lessons learnt during 20 years of the Swedish strategic programme against antibiotic resistance. Bull World Health Organ. 2017;95:764–773.PubMedPubMedCentral
58.
go back to reference European Centre for Disease Prevention and Control. Antimicrobial consumption. In: ECDC. Annual Epidemiological Report for 2017. Stockholm: ESDC; 2018, 2019. European Centre for Disease Prevention and Control. Antimicrobial consumption. In: ECDC. Annual Epidemiological Report for 2017. Stockholm: ESDC; 2018, 2019.
60.
go back to reference Eccles S, Pincus C, Higgins B, Woodhead M, Guideline Development G. Diagnosis and management of community and hospital acquired pneumonia in adults: summary of NICE guidance. BMJ. 2014;349:g6722.PubMed Eccles S, Pincus C, Higgins B, Woodhead M, Guideline Development G. Diagnosis and management of community and hospital acquired pneumonia in adults: summary of NICE guidance. BMJ. 2014;349:g6722.PubMed
61.
go back to reference Wiersinga WJ, Bonten MJ, Boersma WG, et al. Management of community-acquired pneumonia in adults: 2016 guideline update from the Dutch Working Party on Antibiotic Policy (SWAB) and Dutch Association of Chest Physicians (NVALT). Neth J Med. 2018;76:4–13.PubMed Wiersinga WJ, Bonten MJ, Boersma WG, et al. Management of community-acquired pneumonia in adults: 2016 guideline update from the Dutch Working Party on Antibiotic Policy (SWAB) and Dutch Association of Chest Physicians (NVALT). Neth J Med. 2018;76:4–13.PubMed
62.
go back to reference Spindler C, Stralin K, Eriksson L, et al. Swedish guidelines on the management of community-acquired pneumonia in immunocompetent adults–Swedish society of infectious diseases 2012. Scand J Infect Dis. 2012;44:885–902.PubMed Spindler C, Stralin K, Eriksson L, et al. Swedish guidelines on the management of community-acquired pneumonia in immunocompetent adults–Swedish society of infectious diseases 2012. Scand J Infect Dis. 2012;44:885–902.PubMed
63.
go back to reference Mandell LA, Wunderink RG, Anzueto A, et al. Infectious diseases society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44:S27–S72.PubMed Mandell LA, Wunderink RG, Anzueto A, et al. Infectious diseases society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44:S27–S72.PubMed
64.
go back to reference O’Brien KS, Emerson P, Hooper PJ, et al. Antimicrobial resistance following mass azithromycin distribution for trachoma: a systematic review. Lancet Infect Dis. 2019;19:e14–e25.PubMed O’Brien KS, Emerson P, Hooper PJ, et al. Antimicrobial resistance following mass azithromycin distribution for trachoma: a systematic review. Lancet Infect Dis. 2019;19:e14–e25.PubMed
65.
66.
go back to reference Leja M, Cine E, Rudzite D, et al. Prevalence of Helicobacter pylori infection and atrophic gastritis in Latvia. Eur J Gastroenterol Hepatol. 2012;24:1410–1417.PubMed Leja M, Cine E, Rudzite D, et al. Prevalence of Helicobacter pylori infection and atrophic gastritis in Latvia. Eur J Gastroenterol Hepatol. 2012;24:1410–1417.PubMed
67.
go back to reference Lin J, Huang WW. A systematic review of treating Helicobacter pylori infection with traditional Chinese medicine. World J Gastroenterol WJG. 2009;15:4715–4719.PubMed Lin J, Huang WW. A systematic review of treating Helicobacter pylori infection with traditional Chinese medicine. World J Gastroenterol WJG. 2009;15:4715–4719.PubMed
68.
go back to reference Bonifacio BV, dos Santos Ramos MA, da Silva PB, Bauab TM. Antimicrobial activity of natural products against Helicobacter pylori: a review. Ann Clin Microbiol Antimicrob. 2014;13:54.PubMedPubMedCentral Bonifacio BV, dos Santos Ramos MA, da Silva PB, Bauab TM. Antimicrobial activity of natural products against Helicobacter pylori: a review. Ann Clin Microbiol Antimicrob. 2014;13:54.PubMedPubMedCentral
69.
go back to reference Zaidi SF, Muhammad JS, Usmanghani K, Sugiyama T. Review: pharmacological ins and outs of medicinal plants against Helicobacter pylori: a review. Pak J Pharm Sci. 2015;28:1171–1176.PubMed Zaidi SF, Muhammad JS, Usmanghani K, Sugiyama T. Review: pharmacological ins and outs of medicinal plants against Helicobacter pylori: a review. Pak J Pharm Sci. 2015;28:1171–1176.PubMed
70.
go back to reference Shmuely H, Domniz N, Yahav J. Non-pharmacological treatment of Helicobacter pylori. World J Gastrointest Pharmacol Ther. 2016;7:171–178.PubMedPubMedCentral Shmuely H, Domniz N, Yahav J. Non-pharmacological treatment of Helicobacter pylori. World J Gastrointest Pharmacol Ther. 2016;7:171–178.PubMedPubMedCentral
71.
go back to reference Losurdo G, Cubisino R, Barone M, et al. Probiotic monotherapy and Helicobacter pylori eradication: a systematic review with pooled-data analysis. World J Gastroenterol. 2018;24:139–149.PubMedPubMedCentral Losurdo G, Cubisino R, Barone M, et al. Probiotic monotherapy and Helicobacter pylori eradication: a systematic review with pooled-data analysis. World J Gastroenterol. 2018;24:139–149.PubMedPubMedCentral
72.
go back to reference Xiong M, Bao Y, Xu X, et al. Selective killing of Helicobacter pylori with pH-responsive helix-coil conformation transitionable antimicrobial polypeptides. Proc Natl Acad Sci U S A. 2017;114:12675–12680.PubMedPubMedCentral Xiong M, Bao Y, Xu X, et al. Selective killing of Helicobacter pylori with pH-responsive helix-coil conformation transitionable antimicrobial polypeptides. Proc Natl Acad Sci U S A. 2017;114:12675–12680.PubMedPubMedCentral
73.
go back to reference Seabra CL, Nunes C, Gomez-Lazaro M, et al. Docosahexaenoic acid loaded lipid nanoparticles with bactericidal activity against Helicobacter pylori. Int J Pharm. 2017;519:128–137.PubMed Seabra CL, Nunes C, Gomez-Lazaro M, et al. Docosahexaenoic acid loaded lipid nanoparticles with bactericidal activity against Helicobacter pylori. Int J Pharm. 2017;519:128–137.PubMed
74.
go back to reference Seabra CL, Nunes C, Bras M, et al. Lipid nanoparticles to counteract gastric infection without affecting gut microbiota. Eur J Pharm Biopharm. 2018;127:378–386.PubMed Seabra CL, Nunes C, Bras M, et al. Lipid nanoparticles to counteract gastric infection without affecting gut microbiota. Eur J Pharm Biopharm. 2018;127:378–386.PubMed
75.
go back to reference Kwack W, Lim Y, Lim C, Graham DY. High dose ilaprazole/amoxicillin as first-line regimen for Helicobacter pylori infection in Korea. Gastroenterol Res Pract. 2016;2016:1648047.PubMedPubMedCentral Kwack W, Lim Y, Lim C, Graham DY. High dose ilaprazole/amoxicillin as first-line regimen for Helicobacter pylori infection in Korea. Gastroenterol Res Pract. 2016;2016:1648047.PubMedPubMedCentral
76.
go back to reference Park HY, Kang EJ, Kim DG, et al. High and frequent dose of dexlansoprazole and amoxicillin dual therapy for Helicobacter pylori infections: a single arm prospective study. Korean J Gastroenterol. 2017;70:176–180.PubMed Park HY, Kang EJ, Kim DG, et al. High and frequent dose of dexlansoprazole and amoxicillin dual therapy for Helicobacter pylori infections: a single arm prospective study. Korean J Gastroenterol. 2017;70:176–180.PubMed
77.
go back to reference Zullo A, Ridola L, Francesco VD, et al. High-dose esomeprazole and amoxicillin dual therapy for first-line Helicobacter pylori eradication: a proof of concept study. Ann Gastroenterol. 2015;28:448–451.PubMedPubMedCentral Zullo A, Ridola L, Francesco VD, et al. High-dose esomeprazole and amoxicillin dual therapy for first-line Helicobacter pylori eradication: a proof of concept study. Ann Gastroenterol. 2015;28:448–451.PubMedPubMedCentral
78.
go back to reference Dore MP, Lu H, Graham DY. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut. 2016;65:870–878.PubMed Dore MP, Lu H, Graham DY. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut. 2016;65:870–878.PubMed
79.
go back to reference Graham DY, Dore MP, Lu H. Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies. Expert Rev Anti Infect Ther. 2018;16:679–687.PubMedPubMedCentral Graham DY, Dore MP, Lu H. Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies. Expert Rev Anti Infect Ther. 2018;16:679–687.PubMedPubMedCentral
80.
go back to reference Ford AC, Malfertheiner P, Giguere M, Santana J, Khan M, Moayyedi P. Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. World J Gastroenterol WJG. 2008;14:7361–7370.PubMed Ford AC, Malfertheiner P, Giguere M, Santana J, Khan M, Moayyedi P. Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. World J Gastroenterol WJG. 2008;14:7361–7370.PubMed
81.
go back to reference Ko SW, Kim YJ, Chung WC, Lee SJ. Bismuth supplements as the first-line regimen for Helicobacter pylori eradication therapy: systemic review and meta-analysis. Helicobacter. 2019;24:e12565.PubMed Ko SW, Kim YJ, Chung WC, Lee SJ. Bismuth supplements as the first-line regimen for Helicobacter pylori eradication therapy: systemic review and meta-analysis. Helicobacter. 2019;24:e12565.PubMed
82.
go back to reference Nyssen OP, McNicholl AG, Gisbert JP. Meta-analysis of three-in-one single capsule bismuth-containing quadruple therapy for the eradication of Helicobacter pylori. Helicobacter. 2019;24:e12570.PubMed Nyssen OP, McNicholl AG, Gisbert JP. Meta-analysis of three-in-one single capsule bismuth-containing quadruple therapy for the eradication of Helicobacter pylori. Helicobacter. 2019;24:e12570.PubMed
83.
go back to reference Hsu PI, Pan CY, Kao JY, et al. Helicobacter pylori eradication with bismuth quadruple therapy leads to dysbiosis of gut microbiota with an increased relative abundance of Proteobacteria and decreased relative abundances of Bacteroidetes and Actinobacteria. Helicobacter. 2018;23:e12498.PubMed Hsu PI, Pan CY, Kao JY, et al. Helicobacter pylori eradication with bismuth quadruple therapy leads to dysbiosis of gut microbiota with an increased relative abundance of Proteobacteria and decreased relative abundances of Bacteroidetes and Actinobacteria. Helicobacter. 2018;23:e12498.PubMed
84.
go back to reference Shiotani A, Lu H, Dore MP, Graham DY. Treating Helicobacter pylori effectively while minimizing misuse of antibiotics. Cleve Clin J Med. 2017;84:310–318.PubMedPubMedCentral Shiotani A, Lu H, Dore MP, Graham DY. Treating Helicobacter pylori effectively while minimizing misuse of antibiotics. Cleve Clin J Med. 2017;84:310–318.PubMedPubMedCentral
85.
go back to reference Areia M, Carvalho R, Cadime AT, Rocha Goncalves F, Dinis-Ribeiro M. Screening for gastric cancer and surveillance of premalignant lesions: a systematic review of cost-effectiveness studies. Helicobacter. 2013;18:325–337.PubMed Areia M, Carvalho R, Cadime AT, Rocha Goncalves F, Dinis-Ribeiro M. Screening for gastric cancer and surveillance of premalignant lesions: a systematic review of cost-effectiveness studies. Helicobacter. 2013;18:325–337.PubMed
86.
go back to reference Lansdorp-Vogelaar I, Sharp L. Cost-effectiveness of screening and treating Helicobacter pylori for gastric cancer prevention. Best Pract Res Clin Gastroenterol. 2013;27:933–947.PubMed Lansdorp-Vogelaar I, Sharp L. Cost-effectiveness of screening and treating Helicobacter pylori for gastric cancer prevention. Best Pract Res Clin Gastroenterol. 2013;27:933–947.PubMed
87.
go back to reference Ford AC, Forman D, Hunt RH, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ. 2014;348:g3174.PubMedPubMedCentral Ford AC, Forman D, Hunt RH, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ. 2014;348:g3174.PubMedPubMedCentral
88.
go back to reference Hogh MB, Kronborg C, Hansen JM, Schaffalitzky de Muckadell OB. The cost effectiveness of Helicobacter pylori population screening-economic evaluation alongside a randomised controlled trial with 13-year follow-up. Aliment Pharmacol Ther. 2019;49:1013–1025.PubMed Hogh MB, Kronborg C, Hansen JM, Schaffalitzky de Muckadell OB. The cost effectiveness of Helicobacter pylori population screening-economic evaluation alongside a randomised controlled trial with 13-year follow-up. Aliment Pharmacol Ther. 2019;49:1013–1025.PubMed
89.
go back to reference Chen Q, Liang X, Long X, Yu L, Liu W, Lu H. Cost-effectiveness analysis of screen-and-treat strategy in asymptomatic Chinese for preventing Helicobacter pylori-associated diseases. Helicobacter. 2019;24:e12563.PubMed Chen Q, Liang X, Long X, Yu L, Liu W, Lu H. Cost-effectiveness analysis of screen-and-treat strategy in asymptomatic Chinese for preventing Helicobacter pylori-associated diseases. Helicobacter. 2019;24:e12563.PubMed
90.
go back to reference Kowada A. Cost-effectiveness of Helicobacter pylori screening followed by eradication treatment for employees in Japan. Epidemiol Infect. 2018;146:1834–1840.PubMed Kowada A. Cost-effectiveness of Helicobacter pylori screening followed by eradication treatment for employees in Japan. Epidemiol Infect. 2018;146:1834–1840.PubMed
91.
go back to reference Smith R, Coast J. The true cost of antimicrobial resistance. BMJ. 2013;346:f1493.PubMed Smith R, Coast J. The true cost of antimicrobial resistance. BMJ. 2013;346:f1493.PubMed
92.
go back to reference Michaelidis CI, Fine MJ, Lin CJ, et al. The hidden societal cost of antibiotic resistance per antibiotic prescribed in the United States: an exploratory analysis. BMC Infect Dis. 2016;16:655.PubMedPubMedCentral Michaelidis CI, Fine MJ, Lin CJ, et al. The hidden societal cost of antibiotic resistance per antibiotic prescribed in the United States: an exploratory analysis. BMC Infect Dis. 2016;16:655.PubMedPubMedCentral
93.
go back to reference Lee YC, Chiang TH, Liou JM, Chen HH, Wu MS, Graham DY. Mass eradication of Helicobacter pylori to prevent gastric cancer: theoretical and practical considerations. Gut Liver. 2016;10:12–26.PubMedPubMedCentral Lee YC, Chiang TH, Liou JM, Chen HH, Wu MS, Graham DY. Mass eradication of Helicobacter pylori to prevent gastric cancer: theoretical and practical considerations. Gut Liver. 2016;10:12–26.PubMedPubMedCentral
94.
go back to reference Bomme M, Hansen JM, Wildner-Christensen M, Hallas J, Schaffalitzky de Muckadell OB. Effects of community screening for Helicobacter pylori: 13-year follow-up evaluation of a randomized controlled trial. Clin Gastroenterol Hepatol. 2017;15:1715–1723.PubMed Bomme M, Hansen JM, Wildner-Christensen M, Hallas J, Schaffalitzky de Muckadell OB. Effects of community screening for Helicobacter pylori: 13-year follow-up evaluation of a randomized controlled trial. Clin Gastroenterol Hepatol. 2017;15:1715–1723.PubMed
95.
go back to reference Leja M, Park JY, Murillo R, et al. Multicentric randomised study of Helicobacter pylori eradication and pepsinogen testing for prevention of gastric cancer mortality: the GISTAR study. BMJ Open. 2017;7:e016999.PubMedPubMedCentral Leja M, Park JY, Murillo R, et al. Multicentric randomised study of Helicobacter pylori eradication and pepsinogen testing for prevention of gastric cancer mortality: the GISTAR study. BMJ Open. 2017;7:e016999.PubMedPubMedCentral
Metadata
Title
What Would the Screen-and-Treat Strategy for Helicobacter pylori Mean in Terms of Antibiotic Consumption?
Authors
Mārcis Leja
Uga Dumpis
Publication date
01-06-2020
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 6/2020
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-019-05893-z

Other articles of this Issue 6/2020

Digestive Diseases and Sciences 6/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine